<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02761512</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_303</org_study_id>
    <nct_id>NCT02761512</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer</brief_title>
  <official_title>A Double Blind, Randomized, Active-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate non-inferiority of CJ-12420 to lansoprazole 30 mg capsule in terms of
      therapeutic efficacy, and to confirm safety of CJ-12420, after once daily oral administration
      of CJ-12420 50 mg, 100 mg or Lansoprazole 30 mg capsule in gastric ulcer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind, randomized, placebo-controlled, phase 3 study. Subjects will be
      randomly assigned to one of the three treatment groups (CJ-12420 50 mg, 100 mg or
      Lansoprazole 30 mg).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative healing rate of gastric ulcer at 8-week</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Healing rate of gastric ulcer at 4-week</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Week 8 healing rates by H. pylori infection</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Gastric Ulcer</condition>
  <arm_group>
    <arm_group_label>CJ-12420 50 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CJ-12420 50 mg, tablet, once daily, oral administration for up to 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-12420 100 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CJ-12420 100 mg, tablet, once daily, oral administration for up to 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lansoprazole 30 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lansoprazole 30 mg, capsule, once daily, oral administration for up to 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-12420 50 mg QD</intervention_name>
    <description>CJ-12420 50 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 50 mg.</description>
    <arm_group_label>CJ-12420 50 mg QD</arm_group_label>
    <other_name>Not yet decided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-12420 100 mg QD</intervention_name>
    <description>CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 100 mg.</description>
    <arm_group_label>CJ-12420 100 mg QD</arm_group_label>
    <other_name>Not yet decided</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole 30 mg QD</intervention_name>
    <description>Lansoprazole 30 mg capsule will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of Lansoprazole 30 mg.</description>
    <arm_group_label>Lansoprazole 30 mg QD</arm_group_label>
    <other_name>Lanston cap.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Diagnosis of 1 or more active gastric ulcers (≥3 mm ~ ≤30 mm using open biopsy forceps)
        according to the Sakita-Miwa classification (A1 or A2 stage) from upper GI endoscopy at the
        same institution within 14 days prior to initiation of the investigational product
        administration.

        Exclusion Criteria:

          1. Finding of gastrointestinal bleeding, esophageal stricture, ulcer stenosis, pyloric
             stenosis, esophageal gastric varices, Barrett's esophageal of &gt;3 cm (long segment
             Barrett esophagus, LSBE), duodenal ulcer, intractable ulcer, digestive ulcer
             perforation or malignancy on upper GI endoscopy.

          2. Ulcer caused by an endoscopic surgery (e.g., ulcer after EMR/ESD)

          3. Requirement of persistent daily use of drugs that may cause an ulcer such as
             nonsteroidal anti-inflammatory drugs(NSAIDs) or aspirin during the course of the study

          4. Scheduled surgery requiring hospitalization or requirement of surgical treatment
             during study participation

          5. Subjects who participated in the other clinical trial within 4 weeks prior to
             randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung Gyu Choi, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic Univ. Seoul St. Mary Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahrong Kim</last_name>
    <phone>82-2-6740-2441</phone>
    <email>ahrong.kim@cj.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eun ji Kim</last_name>
    <phone>82-2-6740-2443</phone>
    <email>eunji.kim@cj.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Catholic Univ. Seoul St. Mary Hospita</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

